Expert Interview
Discussing How Axsome Therapeutics' AXS-05 (Auvelity) for Alzheimer's Disease Agitation (ADA) will be used Commercially After Receiving FDA Approval
Ticker(s): AXSM, OTSKY, HLBBFInstitution: University of Kansas
- Director of NIH-funded University of Kansas Alzheimer's Disease Center.
- Currently manages 300 patients with Alzheimer's disease.
- Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.
How many Alzheimer's Disease patients do you manage?
Added By: wilson_adminHow big of an issue is managing ADA in practice?
Added By: wilson_adminHow do you intend to use Auvelity?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
